Stay updated on Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial

Sign up to get notified when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.1 to v3.7.2; the clinical trial record history remains unchanged.
    Difference
    0.0%
    Check dated 2026-10-17T14:38:35.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page footer now displays site revision v3.7.1 instead of v3.7.0.
    Difference
    0.0%
    Check dated 2026-10-10T15:39:09.000Z thumbnail image
  3. Check
    20 days ago
    No Change Detected
  4. Check
    33 days ago
    Change Detected
    Summary
    The UI text changed from 'Find Contact Information' to 'Find contact information' to adjust capitalization, and the footer revision label updated from v3.6.6 to v3.7.0.
    Difference
    0.1%
    Check dated 2026-09-19T18:53:30.000Z thumbnail image
  5. Check
    54 days ago
    Change Detected
    Summary
    A new revision entry, v3.6.6, was added to the study record history, and the previous revision, v3.6.5, was removed from the current listing.
    Difference
    0.0%
    Check dated 2026-08-29T20:19:32.000Z thumbnail image
  6. Check
    75 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.6.5, replacing the previous Revision: v3.6.4, indicating a site version update reflected on the page. This update appears to be a platform-level change rather than content changes to the trial record.
    Difference
    0.0%
    Check dated 2026-08-08T22:56:23.000Z thumbnail image
  7. Check
    90 days ago
    Change Detected
    Difference
    0.2%
    Check dated 2026-07-25T12:44:08.000Z thumbnail image

Stay in the know with updates to Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.